ArticleDermatology and therapy2026
Patterns of Clinical Response in Rollover Adolescent Patients with Alopecia Areata Treated with Ritlecitinib in the Ongoing Long-Term, Open-Label, Phase 3 ALLEGRO-LT Study.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A phase 2b/3 randomized, double-blind, placebo-controlled, dose-ranging study to investigate the efficacy and safety of pf-06651600 in adult and adolescent alopecia areata (aa) subjects with 50% or greater scalp hair loss
A phase 3 open-label, multi-center, long-term study investigating the safety and efficacy of pf-06651600 in adult and adolescent participants with alopecia areata
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRitlecitinib, a JAK3/TEC family kinase inhibitor, demonstrated efficacy in adolescents with alopecia areata (AA) in the ALLEGRO phase 2b/3 study. The present study evaluated long-term Severity of Alopecia Tool (SALT) score response patterns in adolescents from ALLEGRO-2b/3 who rolled over into the open-label, phase 3 ALLEGRO-LT study.
methodsThis post hoc analysis included adolescents aged 12-17 years with AA and ≥ 50% scalp hair loss who received ritlecitinib 50 mg daily, with or without a 4-week 200-mg loading dose. Individual SALT score trajectories from baseline to month 24 were used to categorize adolescents as early (SALT score ≤ 20 at week 24 and months 12 and 24), middle (SALT ≤ 20 at months 12 and 24), or late responders (SALT ≤ 20 at month 24) or partial responders (maintained 30% improvement), relapsers (achieved but did not maintain 30% improvement), or true non-responders (did not achieve 30% improvement). Baseline disease characteristics were assessed by SALT score ≤ 20 response status.
resultsAmong 57 adolescents, 42.1% had SALT score ≤ 20 response through month 24 (17.5% early, 17.5% middle, and 7.0% late responders). The remaining 57.9% did not achieve SALT score ≤ 20 response, with 15.8% partial responders, 21.1% relapsers, and 21.1% true non-responders. SALT score ≤ 20 responders had shorter AA episode duration, less frequent alopecia totalis/universalis, and were more frequently female versus non-responders.
conclusionA large proportion of adolescents treated with ritlecitinib had an early, middle, or late SALT score ≤ 20 response pattern during 24 months of treatment. Responders (SALT score ≤ 20) had less extensive scalp hair loss and shorter AA episode duration at baseline, and a higher proportion of responders were female compared with non-responders (SALT score > 20). Infographic available for this article. CLINICALTRIALS: GOV REGISTRATION: NCT03732807 and NCT04006457.
Indexed as
Identifiers
42823604What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.